Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study-Reference-Cited by-同舟云学术

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study

Published:2011-04 Issue:6 Volume:47 Page:831-838
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

van der Bol Jessica M.,Loos Walter J.,de Jong Floris A.,van Meerten Esther,Konings Inge R.H.M.,Lam Mei H.,de Bruijn Peter,Wiemer Erik A.C.,Verweij Jaap,Mathijssen Ron H.J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Drug interactions in oncology;Beijnen;Lancet Oncol,2004

2. Lansoprazole and omeprazole in the treatment of acid peptic disorders;Blum;Am J Health Syst Pharm,1996

3. Proton pump inhibitors and their drug interactions: an evidence-based approach;Gerson;Eur J Gastroenterol Hepatol,2001

4. Omeprazole inhibits elimination of diazepam;Gugler;Lancet,1984

5. Effect of omeprazole and cimetidine on plasma diazepam levels;Andersson;Eur J Clin Pharmacol,1990

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration;Cancer Treatment Reviews;2024-09

2. Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles;Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: From Basic Concepts to Applications;2024

3. Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients;Biomedicine & Pharmacotherapy;2023-07

4. Proton Pump Inhibitors and Cancer: Current State of Play;Frontiers in Pharmacology;2022-03-14

5. Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy;Current Drug Metabolism;2022-02